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HIV-1non-codingexon3caneitherbe spliced toexons4, 4a, 4b,
4c, and 5 to generate tat, rev, and nef mRNAs or remain unspliced
to produce the 13a7 vpr mRNA. Here we show that serine- and
arginine-rich proteins 55 and 75 (SRp55 and SRp75) inhibit splic-
ing from the 5-splice site of exon 3 thereby causing an accumula-
tion of the partially unspliced 13a7 vprmRNA. In contrast, serine-
and arginine-rich protein 40 (SRp40) induces splicing from exon 3
to exon 4, thereby promoting the production of the 1347 tat
mRNA. We demonstrate that SRp55 stimulates vpr mRNA pro-
duction by interacting with the previously identified HIV-1 splic-
ing enhancer named GAR and inhibiting its function. This inhibi-
tion requires both serine arginine-rich andRNA-binding domains
of SRp55, indicating that production ofHIV-1 vprmRNAdepends
on the interaction of SRp55 with an unknown factor.
To produce all the mRNAs that are needed for HIV-1 to be
infectious it uses alternative splicing. The full-length 9-kb tran-
script contains several splice sites, including four 5-splice sites,
also called splice donors (SD1–4)2 and eight 3-splice sites, also
called splice acceptors (SA2–3, -4a–c, -5, and -7) (supple-
mental Fig. 1A), which can all be used in different combinations
to create more than 35 differently spliced mRNAs (sup-
plemental Fig. 1, B and C) (1–6). Cloning and expression of
individual HIV-1mRNAs have revealed that mRNAs spliced to
SA3 produce Vpr, those spliced to SA4 produce Tat, those
spliced to SA4a and -4b produce Rev andNef, and those spliced
to SA5 produce Nef (1, 2, 7, 8). mRNAs spliced to SA2 are
believed to produce Vif (5, 7). Two additional mRNAs that are
believed to produce Rev and Nef are spliced to SA4c or to SA7,
respectively (4). To produce the correct amounts of all mRNAs,
the splice acceptors in HIV-1 are sub-optimal because of short
and interrupted polypyrimidine tracts, non-canonical branch
points, and inhibitory sequences that down-regulate the usage
of several splice sites (6, 9–13).
Enhancer or silencer sequences regulate alternative splicing
by up-regulating or down-regulating the usage of a splice site
(14). Generally, the family of serine- and arginine-rich proteins
(SR proteins) target enhancer sequences, and silencer se-
quences are targeted by heterogeneous nuclear ribonucleopro-
teins (15). There are several enhancers and silencers on HIV-1
pre-mRNA (16). A silencer in exon 3 called ESSV inhibits the
vpr splice acceptor SA3 (10, 17). Two silencers in exon 4, named
ESS2 and ESS2p, inhibit splicing into exon 4 thereby inhibiting
the production of tat mRNA (18, 19). SA7 is used by all mRNAs
in the 2-kb class. In exon 7 a silencer called ESS3 blocks U2
small nuclear ribonucleoprotein, thereby suppressing SA7
(19–21). An intronic silencer that blocks SA7 is located in the
intron, directly upstream of exon 7 (22). An enhancer element
called ESE3 that activates SA7 is located close to ESS3 in exon 7
(9, 21, 23). An enhancer in exon 4 has been named ESE2,
because it attenuates ESS2 and thereby enhances splicing into
SA4 (24). In exon 5, an enhancer named GAR stimulates the
usage of highly active SA5 and adjacent 3-splice sites as well as
SD5, which is used for production of the entire small mRNA
size class (25, 26). HIV-1 vpr mRNA 13a7 contains an intron
between exon 3 and exon 4 and is, therefore, partially spliced.
Little is known about the regulation of vpr mRNA production.
The human SR proteins currently contain at least 10 known
members, including SRp20, SRp30a–c, SRp40, SRp46, SRp54,
SRp55, SRp75, and 9G8. SR proteins regulate alternative splic-
ing by stimulating or repressing the usage of splice sites (27).
The complex splicing of the HIV-1 pre-mRNA indicates that
HIV-1 is dependent on multiple splicing factors to generate all
mRNAs. Recent studies have shown that the relative concen-
trations of SR proteins are of paramount importance for pro-
duction of sufficient quantities of the various HIV-1 mRNAs
(16). SR proteins have also been shown to be potential targets
for novel therapy against HIV-1 infection (28). It is therefore of
interest to identify the cellular splicing factors that regulate
HIV-1 mRNA splicing.
EXPERIMENTAL PROCEDURES
Plasmid Constructions—To construct the subgenomic plas-
mid pDP (Fig. 2A) HIV-1 sequences from position 246–1571
(all numbers refer to the HXB2R sequence) were PCR-am-
plified using oligonucleotides BSS and APAA (Table 1) and
cloned into pCR2.1-TOPO (Invitrogen) and subsequently
inserted into pNL13aE (7) using BssHII and SalI, resulting in
pNL13aEBA. Nucleotide 3516–5348 was PCR-amplified
using oligonucleotides MLUS and SALA (Table 1) and sub-
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental Fig. 1.
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cloned into pCR2.1-TOPO. This fragment was cloned into
pNL13aEBA using MluI and SalI, creating pDP (Fig. 2A).
pNL13a7 has been described previously (7). pNL13a7dG was
constructed by PCR mutagenesis (246–5522 and 5556–8031)
using oligonucleotides BSS, dGARas, dGARs, and BAMA
(Table 1) and cloned into pNL13a7 (7) using SalI and BamHI.
pNL13a7d was generated by PCR amplification of nucleotides
5393–8031with oligonucleotidesDownsa4s andBAMA(Table
1) and cloning into pCR2.1-TOPO. The fragment was excised
with SalI and BamHI and cloned into pNL13a7. Plasmid
pNL13a7d4 was constructed by PCR amplification of nucleo-
tide 5480–8031 using oligonucleotides 5480s and BAMA
(Table 1). The PCR fragment was subcloned into pCR2.1-
TOPO and subsequently inserted into pNL13a7 using SalI and
BamHI. pNL13a7sd1 was constructed by PCR amplification of
nucleotides 245–569 using oligonucleotides BSS and sd1as
(Table 1). The PCR fragment was subcloned into pCR2.1-
TOPO and subsequently inserted into pNL13a7 using BssHII
and EcoRI. Transfer of a SalI-BamHI fragment from
pNL13a7dG to pNL13a7sd1 created pNL13a7sd1dG. To gen-
erate pNL13a7de3 PCRmutagenesis was performedwith oligo-
nucleotides exon1s, dexon3as, dexon3s, and sd5as (1–286 and
5007–5591) (Table 1). Themutated fragment was inserted into
pNL13a7 using BssHII and SalI. Plasmid pNL13a7di3 was con-
structed by first PCR-amplifying nucleotides 245–289 and
4936–5055 using oligonucleotides BSS and di3sd3as (Table 1)
followed by cloning into pNL13a7 (7) using BssHII and EcoRI.
The plasmids pT1sd and pT1sde have been described previ-
ously (29). Plasmid pT1–5/GAR was generated by first PCR-
amplifying HIV-1 sequences between nucleotides 5523 and
5591 using oligonucleotides AnnealGARBss/XbaS andAnneal-
GARBss/XbaAS (Table 1). The PCR fragment was inserted into
pT1sd using BssHII and XbaI. Plasmid SRp55dRS was gener-
ated by PCR amplification of nucleotides 1–543 from SRp55
cDNA using oligonucleotides SRp55s and SRp55RRMAS
(Table 1). The PCR fragment was cleavedwith BssHII andXhoI
and cloned into plasmid pCL086 (30). Recombinant plasmid
gst-SRp55 was generated by first PCR-amplifying sequences
from SRp55 cDNA using oligonucleotides SRp55gsts and
SRp55gstas (Table 1). The PCR fragment was cleaved with
BamHI and EcoRI and subcloned into pGEX-2T (Amersham
Biosciences). SR protein expression plasmids have been
described previously (31–33).
Transfections—Transfections of plasmid DNA into HeLa
cells were performed according to the FuGENE 6 method
(RocheMolecular Biochemicals).Whennothing else is stated, 1
g of each plasmidwas transfected into 60-mmdiameter plates
containing subconfluentHeLa cells. Transfected cells were har-
vested 24 h post-transfection.
RNA Extraction, Northern Blotting, and Radiolabeled DNA
Probe Synthesis—Cytoplasmic RNA extraction was performed
as previously described (34). Northern blot analysis was per-
formed by size separation of 10 g of cytoplasmic RNA on a
1.5% agarose gels containing 2.2 M formaldehyde followed by
transfer of RNA to nitrocellulose filter and hybridization. The
exon1probewas generated by PCRamplification of nucleotides
1–289 of the HIV-1 genome (HXB2R) with oligonucleotides
Exon1s and Exon1as (Table 1). The probe was [-32P]dCTP-
labeled by randompriming with a Decaprime kit (Ambion Inc.)
according to the manufacturer’s instructions.
RT-PCR—Cytoplasmic RNA was reverse-transcribed at 37 °C
for 50 min using random hexamers as described previously (35).
200 ng of RNA was used for each RT-PCR reaction in a total vol-
ume of 20l. A total of 1l of cDNAproduct was PCR-amplified
using the oligonucleotides indicated for each experiment.
siRNA Analysis—Knockdown of protein was performed by
using a pool of four siRNAs targeting SRp55 and four siRNAs
targeting SRp75 (siGENOME SMARTpool, Dharmacon). A
final concentration of 133 nM of each siRNA pool was reverse-
transfected into HeLa cells at the time of passage. 48 h later,
siRNA-transfected cells growing in 35-mm plates were trans-
fectedwith 0.5g of pNL13a7 plasmidDNA as described in the
previous section. Cells were harvested 24 h post plasmid trans-
fection and subjected to RNA extraction and analysis.
Western Blotting—Western blotting was performed as previ-
ously described (36).
gst-SRp55 Purification—Purified gst-SRp55 was prepared by
using glutathione-Sepharose (GS) beads as specified by the
manufacturer (Amersham Biosciences). Briefly, a culture of
Escherichia coli BL21 transformed with pGEX-SRp55 was
induced with 0.1 mM isopropyl--D-thiogalactopyranoside for
2 h. The bacteria were pelleted and resuspended in ice-cold
phosphate-buffered saline and lysed by sonication followed by
incubation in 1% Triton X-100. Debris was pelleted, and gst-
SRp55 was purified using the GS-beads.
In Vitro Transcription and RNA Gel Shift Assay—In vitro
transcription was performed on a PCR fragment containing
bacteriophage T7 promoter upstream of GAR using T7 RNA
polymerase (Ambion Inc.). The control RNA was transcribed
from a T7 promoter-driven plasmid encoding a sequence from
TABLE 1







































SRp55 Induces vpr mRNA Production
31538 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285 • NUMBER 41 • OCTOBER 8, 2010
human papilloma virus type 1 named AUM/UM (34). The
RNAs were labeled with [-32P]CTP, and competitor GAR
RNA was synthesized in the absence of radiolabeled nucleo-
tide. RNA gel-shift assays were performed with gst-SRp55 or
gst at room temperature in 20l of binding buffer (120mMKCl,
10 mM HEPES (pH 7.6), 3 mM MgCl2, 1 mM dithiothreitol, and
5% (v/v) glycerol). After 20 min the RNA-protein complexes
were resolved on non-denaturing 7.5% polyacrylamide gels
(acrylamide-bisacrylamide, 29:1). The complexes were visual-
ized by autoradiography.
RESULTS
SRp55 and SRp75 Inhibit Splicing from Exon 3 and Induce
Production of 13a7 vpr mRNA—The HIV-1 vpr mRNA is
encoded by mRNAs containing either exon 3a or 3aE
(supplemental Fig. 1,A andB). vprmRNA13a7 is special in that
it is incompletely spliced, but lacks the RRE and thus cannot be
induced by Rev (supplemental
Fig. 1C). To identify proteins that
regulate vpr expression, we used a
cDNA plasmid named pNL13a7
that expresses the 13a7 vpr mRNA
(7) (Fig. 1A). However, the majority
of this mRNA is further spliced
from the unique 5-splice site of
exon 3 to exons 4, 4a, 4b, 4c, or 5 (7)
(Fig. 1A). Northern blotting on
cytoplasmic RNA extracted from
cells transfected with pNL13a7 and
SR protein expression plasmids
revealed that SRp40 shifted the
splicing of mRNAs generated by
pNL13a7 to mRNAs migrating
higher up in the gel (Fig. 1B). SRp55
and SRp75 totally inhibited splicing
and promoted production of high
levels of unspliced 13a7 vpr mRNA
in the cytoplasm (Fig. 1B). In con-
trast, SRp20, SRp30c, and SC35 had
an unspecific inhibitory effect on
expression of the HIV-1 mRNAs
(Fig. 1, B and C). RT-PCR with oli-
gonucleotides Exon3s and BAMA
(Fig. 1A) showed that SRp40
induced production of tat mRNAs
spliced from exon 3 to exon 4 (Fig.
1C) and that SRp55 and SRp75
inhibited splicing. The latter pro-
teins increased the levels of
unspliced 13a7 vpr mRNA at the
expense of all spliced HIV-1
mRNAs (Fig. 1C). Taken together,
the results in Fig. 1, B and C, dem-
onstrate that SRp40 enhances splic-
ing from exon 3 to exon 4, whereas
SRp55 and SRp75 inhibit splicing
from exon 3 and promote produc-
tion of 13a7 vpr mRNA. Western
blot analysis showed expression of SR protein from the SR pro-
tein expression plasmids (Fig. 1D).
Overexpression of SRp55 and SRp75 Induces Production of
13a7 vpr mRNA in the Context of the Sub-genomic HIV-1 Plas-
mid pDP—We wished to study the effect of SR proteins on vpr
mRNA in the context of all HIV-1 splice sites present. We con-
structed a plasmid named pDP (Fig. 2A) that contains the entire
HIV-1 genome except for a 2-kb deletion in the pol gene. Oli-
gonucleotide Exon3s was used in combination with oligonu-
cleotide BAMA to specifically detectmRNAs that contain exon
3 and 3a (supplemental Fig. 1, C and A). The results revealed
that SRp40 redirected splicing from production of primarily
1357 mRNA to 1347 tat mRNA, as expected (Fig. 2B). In con-
trast, SRp55 inhibited splicing from exon 3 and induced pro-
duction of 13a7 vpr mRNA from pDP (Fig. 2B). Northern blot-
ting of HIV-1 mRNAs produced from pDP in the absence or
















































































FIGURE 1. A, schematic representation of the HIV-1 subgenomic plasmid pNL13a7 (7). The mRNAs produced
from the plasmid are indicated below as well as the oligonucleotides used for RT-PCR and probe used for
northern blotting. B, Northern blot of total cytoplasmic RNA extracted from HeLa cells transfected with
pNL13a7 (7) in the absence or presence of CMV promoter-driven plasmids expressing SRp20, SRp30c, SRp40,
SRp55, SRp75, or SC35. The blot was probed with exon 1 probe (A) detecting all HIV-1 mRNAs. Various mRNAs
detected by the probe are indicated. C, RT-PCR on the RNA used in B performed with oligonucleotides Exon3s
and BAMA (A). Bands representing mRNAs are indicated. M represents the molecular weight marker. D, SR
proteins were detected by Western blot analysis using monoclonal antibody 1H4. Monoclonal antibody detec-
tion of enolase was used as loading control.
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SRp55 caused production of mRNAsmigrating higher than the
2-kb mRNAs detected in the absence of exogenous SRp55 (Fig.
2C). SRp75 had a similar effect on the mRNAs produced from
pDP (Fig. 2C). This was confirmed by RT-PCR analysis of the
same RNA samples with the exon
3-specific oligonucleotides Exon3s
and BAMA (Fig. 2D). These experi-
ments demonstrated a robust in-
crease in production of 13a7 vpr
mRNA in anSRp55- or SRp75-dose-
dependent manner (Fig. 2D).
Induction of 13a7 vpr mRNA by
SRp55 and SRp75 Is Dependent on
SD3 in Exon 3—To investigate
if SRp55 and SRp75 inhibited SD3
specifically, we replaced splice
donor 3 (SD3) in pNL13a7 with
splice donor 1 (SD1) from pDP,
resulting in pNL13a7sd1 (Fig. 3A).
SRp55 and SRp75 did not induce
production of unspliced vpr mRNA
from plasmid pNL13a7sd1 with
SD1, whereas high levels of
unspliced 13a7 vpr mRNA were
induced from wild-type plasmid
pNL13a7 with SD3, as expected
(Fig. 3B). RT-PCR confirmed that
SRp55 and SRp75 primarily induced
production of unspliced 13a7 vpr
mRNA in the presence of SD3 (Fig.
3C), whereas SRp55 and SRp75
induced production of 1347 tat
mRNA in the presence of SD1 (Fig.
3C). Overexpression of SRp75 also
strongly induced splicing to a cryp-
tic splice acceptor in exon 5, in the
presence of SD1 (Fig. 3C). SRp40
induced production of tat mRNA
independently of SD1 or SD3 and
did not inhibit splicing to produce
vpr mRNA 13a7 as shown by RT-
PCR (Fig. 3D). In conclusion, SRp55
and SRp75 stimulate splicing from
SD1 to SA4 to generate 147 tat
mRNA and inhibit splicing from
SD3 to generate 13a7 vpr mRNAs.
To confirm that SRp55 and SRp75
had different effects on SD1 and
SD3 also in the context of the sub-
genomic HIV-1 expression plasmid pDP, in which all HIV-1
splice sites are present, we analyzed mRNAs produced from
pDP in the absence or presence of SRp40, SRp55, and SRp75
with primers that were specific for mRNAs spliced at SD1 (BSS
FIGURE 2. A, schematic representation of the HIV-1 subgenomic plasmid pDP, which is derived from pNL43 (48) and contains a deletion between nucleotides
1571 and 3516 (numbers refer to HXB2R sequence). The three HIV-1 mRNA size classes, and vpr mRNA 13a7, are indicated below plasmid pDP. Arrows indicate
oligonucleotides used for RT-PCR. The Northern blot probe is indicated. B, RT-PCR on cytoplasmic RNA extracted from HeLa cells transfected with pDP in the
absence or presence of pCMVSRp40 or pCMVSRp55. Duplicate transfections are shown. The RT-PCR was performed with the oligonucleotides Exon3s
and BAMA (A). The different bands represent the indicated mRNAs. C, Northern blot of cytoplasmic RNA extracted from HeLa cells transfected with pDP
in the absence or presence of increasing concentrations of pCMVSRp55 or pCMVSRp75. The mRNA size classes are indicated. *, the shift in migration of
2-kb mRNAs. D, the RNAs in C were used for RT-PCR with oligonucleotides Exon3s and BAMA (A) that detect mRNAs containing exon 3. E, RT-PCR on
cytoplasmic RNA extracted from HeLa cells transfected with pDP in the absence or presence of pCMVSRp40, pCMVSRp55, or pCMVSRp75. The RT-PCR






















































FIGURE 3. A, schematic representation of the HIV-1 subgenomic plasmids pDP and pNL13a7sd1. Nucleotide
positions of the deletions and insertions are indicated. The sequences of the different splice donors SD1 and
SD3 are shown and compared with an optimal U1 snRNA binding site. B, Northern blot of cytoplasmic RNA
extracted from HeLa cells transfected with pNL13a7 (w) (7) or pNL13a7sd1 (sd1) in the absence or presence of
CMV promoter-driven plasmids expressing SRp55 or SRp75. The blot was probed with exon 1 probe (Fig. 2A),
detecting all HIV-1 mRNAs. Identified mRNAs are indicated. C, the RNAs in B were subjected to RT-PCR with
oligonucleotides Exon1s and BAMA (Fig. 1A) detecting all mRNAs. Bands representing mRNAs are indicated. M
represents the molecular weight marker. Gapdh amplification was used as a control. D, RT-PCR performed on
cytoplasmic RNA extracted from HeLa cells transfected with HIV-1 subgenomic plasmids pNL13a7 (w) or
pNL13a7sd1 (sd1) in the absence or presence of CMV promoter-driven plasmid-expressing SRp40. Oligonu-
cleotides Exon1s and BAMA (Fig. 1A) were used to detect all HIV-1 mRNAs. The bands representing mRNAs are
indicated. M represents the molecular weight marker.
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and BAMA) and with primers that are specific for mRNAs
using SD3 (Exon3s and BAMA). The locations of the primers
are shown in Fig. 2A. The results shown in Fig. 3 predicted that
SRp40 should enhance splicing to exon 4 from both SD1 and
SD3 to produce 147 and 1347 tatmRNAs, respectively. RT-PCR
with primer pairs Exon3s and BAMA revealed that SRp40
induced splicing fromSD3 to exon 4 to produce 1347 tatmRNA
(Fig. 2B), and RT-PCR with primers BSS and BAMA revealed
that SRp40 induced splicing from SD1 to exon 4 to produce 147
tat mRNA (Fig. 2E).
The results shown in Fig. 3 also predicted that SRp55 and
SRp75 should enhance splicing to exon 4 from SD1 to produce
147 tat mRNAs, but should inhibit splicing from SD3, to gen-
erate the 13a7 vprmRNA. This was indeed the case, as RT-PCR
with primer pairs Exon3s and BAMA revealed that SRp55 and
SRp75 inhibited splicing from SD3 to exon 4 to produce 13a7
vprmRNA (Fig. 2,B andD), whereas RT-PCRwith primers BSS
and BAMA revealed that SRp55 and SRp75 induced splicing
from SD1 to exon 4 to produce 147 tat mRNA (Fig. 2E). We
concluded that high levels of SRp55 and SRp75 enhanced splic-
ing from SD1 to exon 4 and inhibited splicing from SD3 to
induce production of 13a7 vpr mRNA.
Inhibition of the 5-Splice Site of Exon 3 by SRp55 and SRp75
Is Not Dependent on Sequences in Exon 3 or Intron 3—To iden-
tify HIV-1 sequences that were targeted by SRp55 and SRp75,
deletions were introduced in exon 3 or intron 3 (sequences
between SD3 and SA4) in pNL13a7 (Fig. 4A). Overexpression of
SRp55 and SRp75 induced produc-
tion of unspliced 13a7 vprmRNA in
the absence of exon 3 sequences
(Fig. 4B) or intron 3 sequences (Fig.
4C). However, the inhibitory effect
of SRp75 on vprmRNA splicing was
lower in the absence of exon 3 (data
not shown). In addition, we ob-
served that the deletion in exon 3
increased splicing efficiency (Fig.
4B), probably due to deletion of pre-
viously described splicing inhibitory
sequences (10, 17). In contrast, the
deletion in intron 3 reduced splicing
efficiency (Fig. 4C), suggesting that
splicing regulatory elements may be
located downstream of exon 3. We
concluded that SRp55 and SRp75
targeted other HIV-1 sequences
than those of exon 3 or the intronic
region between exon 3 and exon 4.
Deletions in Exon 4, Upstream of
Exon 5, Do Not Affect the Ability of
SRp55 and SRp75 to Induce Produc-
tion of Unspliced 13a7 vpr mRNA,
But Affect the Ability of SRp40 to
Induce Tat mRNA Splicing—A re-
gion in exon 4 described as a
splicing enhancer (ESE2) (24) was
deleted in pNL13a7, resulting in
pNL13a7d (Fig. 5A). The deletion of
ESE2 was analyzed by Northern blotting and RT-PCR, and the
results revealed that deletion of ESE2 reduced splicing effi-
ciency (Fig. 5, B andC) as expected. Northern blot experiments
also showed that deletion of ESE2 in exon 4 did not affect the
ability of SRp55 and SRp75 to induce production of 13a7 vpr
mRNA (Fig. 5B). This finding was confirmed by RT-PCR (Fig.
5C). In addition, the ability of SRp40 to redirect splicing to exon
4 was largely independent of ESE2 (Fig. 5, B and C). However,
introduction of a larger deletion in exon 4 (pNL13a7d4) (Fig.
5A) reduced the ability of SRp40 to induce 1347 tatmRNA (Fig.
5D). The same deletion did not affect the ability of SRp55 and
SRp75 to induce the production of unspliced 13a7 vpr mRNA
(Fig. 5D). We concluded that SRp40 was dependent on se-
quences in exon 4, whereas the target sequence of SRp55 and
SRp75most likely is located downstream of nucleotide position
5478 in exon 4.
Splicing to Exons 4a, 4b, 4c, and 5 in vpr cDNA 13a7 Is
Reduced When a Previously Identified Splicing Regulatory Ele-
ment in Exon 5, Termed GAR, Is Deleted—We had established
that neither exon 3 nor intron 3, nor exon 4 sequences
upstream of exon 5, were required for the splicing inhibitory
effect of SRp55 and SRp75. Next we investigated if SRp55 or
SRp75 acted on the remaining sequences of exon 4 that overlap
with exon 5 and contain a previously identified exonic splicing
enhancer named GAR (25, 26) (Fig. 6A). Deletion of GAR in
pNL13a7, generating pNL13a7dG (Fig. 6A), resulted in mainly
unspliced 13a7 vprmRNAproduction, as can be seen byNorth-



















































FIGURE 4. A, schematic representation of HIV-1 subgenomic plasmids pNL13a7 (7), pNL13a7de3, and
pNL13a7di3. Nucleotide positions of deletions are indicated. B and C, Northern blots with RNA extracted from
HeLa cells transfected with pNL13a7 (w), pNL13a7de3 (de3), or pNL13a7di3 (di3) in the absence or presence of
CMV promoter-driven plasmids expressing SRp55 or SRp75. The blots were probed with exon 1 probe (Fig. 1A)
detecting all HIV-1 mRNAs. Detected mRNAs are indicated.
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ern blotting (Fig. 6B) and by RT-PCR (Fig. 6C). This deletion
inhibited splicing from exon 3 to exons 4a, 4b, 4c, and 5, but
enhanced splicing to exon 4 (Fig. 6,B andC). Overexpression of
SRp40 with the GAR deletionmutant pNL13a7dG resulted in a
very inefficient induction of 1347 tat mRNA, indicating that
SRp40 was dependent on GAR (Fig. 6C), as expected from pre-
viously published results (25). Similar results were obtained by
Northern blotting (Fig. 6D). However, because low levels of tat
mRNAwere detected in the presence of SRp40 (Fig. 6C), SRp40
may act also through other sequences than GAR. Overexpres-
sion of SRp55 and SRp75 did not alter the phenotype of the
pNL13a7dG (Fig. 6B). However, RT-PCR analysis revealed that
the induction of 1347 tat mRNA, caused by the deletion of
GAR, was inhibited by SRp55 and SRp75 (Fig. 6C). Although
SRp55 and SRp75 could still inhibit the 5-splice site of exon 3
in the absence of GAR, the similar phenotype of the GAR dele-
tion and overexpression of SRp55
and SRp75 indicated that SRp55 and
SRp75 might act at least partly by
inhibiting GAR.
To investigate the relationship
between GAR and SRp55 further,
we replaced SD3 with SD1 in the
GAR-deleted pNL13a7 plasmid,
resulting in pNL13a7sd1dG (Fig.
6A). Previous results shown in Fig.
3, B and C, predicted that SRp55
should induce splicing from SD1
(the 5-splice site of exon 1) to SA4
(the 3-splice site of exon 4) and that
it should not inhibit splicing from
SD1. As predicted, SRp55 induced
splicing to exon 4 in the presence
of SD1 in pNL13a7sd1 but failed to
affect splicing when GAR was
deleted in the same plasmid
(pNL13a7sd1dG) (Fig. 6E) support-
ing the idea that SRp55 acts through
GAR.
The phenotype of pNL13a7sd1dG
was similar to the phenotype of
pNL13a7dG (Fig. 6,C and E). SRp55
did not alter the splicing of
pNL13a7sd1dG, whereas induction
of splicing from SD1 to SA4 was
seen when GAR was present
(pNL13a7sd1) (Fig. 6E). We con-
cluded that GAR is required for
splicing to exons 4a, 4b, 4c, and 5,
and that at least part of the splicing
inhibitory effect of SRp55 and
SRp75 was through GAR.
SRp55 Inhibits the Function of
GAR in the Absence of Other HIV-1
Sequences—To further substantiate
the finding that SRp55 inhibits the
function of GAR specifically, we
inserted a 69-nucleotide HIV-1
sequence encoding exon 5 and containing the GAR sequence
(Fig. 7B) into an enhancerless human papillomavirus type 16
(HPV-16) plasmid named pT1sd (29) (Fig. 7A). This plasmid
has the potential to produceHPV-16L1mRNAs,which contain
an internal exon, and L1i mRNAs, which lack the internal exon
(Fig. 7A). Transfection of pT1sd plasmid into HeLa cells gives
rise to primarily L1i mRNA as the splicing enhancer in the
internal exon has been deleted (Fig. 7C). If the HIV-1 GAR
enhancer or the core HPV-16 enhancer (E) was added back into
the internal exon of pT1sd to generate pT1–5/GAR and pT1sde
(29), respectively (Fig. 7A), splicing shifted to L1mRNA (Fig. 7C).
These results confirmed previously published results that GAR
acts as a splicing enhancer in a heterologous context (25, 26).
If SRp55 inhibits the function of GAR specifically, overex-
pression of SRp55 should restore production of L1i mRNA
from pT1–5/GAR, but not from pT1sd or pT1sde. The three
ESE2
(          )pNL13a7d
pNL13a7
























































































FIGURE 5. A, schematic representation of a segment of HIV-1 subgenomic plasmids pNL13a7 (7), pNL13a7d,
and pNL13a7d4. Nucleotide positions of deletions are indicated. B, Northern blot with RNA extracted from
HeLa cells transfected with pNL13a7 (w) or pNL13a7d (d) in the absence or presence of CMV promoter-driven
plasmids expressing SRp40, SRp55, or SRp75. The Northern blot was probed with exon 1 probe (Fig. 1A)
detecting all HIV-1 mRNAs. Detected mRNAs are indicated. C, RT-PCR with oligonucleotides Exon3s and BAMA
(Fig. 1A) performed on the RNAs also analyzed in B. Bands representing mRNAs are indicated. M represents the
molecular weight marker. D, RT-PCR on RNA extracted from HeLa cells transfected with pNL13a7 (w) or
pNL13a7d4 (d4) in the absence or presence of plasmids expressing SRp40, SRp55, and SRp75. The oligonucleo-
tides used were Exon3s and BAMA (Fig. 1A). Bands representing mRNAs are indicated. M represents the molec-
ular weight marker.
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subgenomic HPV-16 plasmids were transfected in the absence
or presence of SRp55 plasmid. The results revealed that SRp55
altered the splicing pattern of pT1–5/GAR by inducing L1i
mRNAs (Fig. 7C). This is a result of exclusion of HPV-16 inter-
nal exon that is depending on a functional enhancer down-
stream of HPV-16 3-splice site at nucleotide position 3358
(Fig. 7C). This effect was specific for the GAR-containing
HPV-16 plasmid pT1–5/GAR, because the plasmids without
GAR (pT1sd and pT1sde) were unaffected by SRp55 (Fig. 7C).
The effect of SRp55 was concentration-dependent, but splicing
did not shift completely fromL1 to L1i (Fig. 7D), not even in the
presence of 10 g of co-transfected SRp55 plasmid. These
results suggested that GAR acted very efficiently even in con-
text of HPV-16. We concluded that SRp55 specifically inhibits
the function of the HIV-1 GAR splicing enhancer.
SRp55 Interacts Directly with the
GAR Splicing Enhancer in Exon 5—
We speculated that SRp55 binds
directly to GAR. Indeed, the
ESEfinder (37, 38) predicted an
SRp55 binding site in GAR (Fig. 8A)
as previously reported (25). To
determine if SRp55 was binding to
GAR, an RNA gel shift assay was
performed with gst-SRp55 and
radiolabeled exon 5 GAR RNA (Fig.
8A). These experiments demon-
strated that gst-SRp55 could bind
directly to GAR (Fig. 8B). In compe-
tition experiments, unlabeled GAR
RNA inhibited SRp55 binding to
radiolabeled GAR RNA, indicating
that the binding of SRp55 to the
GAR enhancer was specific (Fig.
8B). Gst-SRp55 did not bind to a
control RNA derived from human
papillomavirus type 1 named AUM/
UM (34) (Fig. 8C), further support-
ing that SRp55 binds specifically to
HIV-1 GAR.
SRp55 and SRp75 Counteract the
Effect of SRp40 on HIV-1 Splicing—
Having established that SRp40 and
SRp55 had different effects on
HIV-1 vpr mRNA 13a7 and consid-
ering that SRp40 as well as SRp55
can act through GAR, we investi-
gated if SRp40 and SRp55 were
competing forGAR.Transfection of
pNL13a7 with a constant, high
amount of SRp40 and a serial dilu-
tion of either SRp55 or SRp75
showed that SRp40 induced pro-
duction of tat mRNA 1347 in the
presence of low levels of SRp55 and
SRp75, as expected (Fig. 9A). How-
ever, increasing the levels of SRp55
or SRp75 resulted in a shift toward
production of mainly unspliced vpr mRNA 13a7 (Fig. 9A). We
concluded that production of tat mRNA 1347 or vpr mRNA
13a7 is determined by the relative concentration of SRp40 ver-
sus SRp55 or SRp75. If this competition was solely due to a
competition for binding to GAR, an SRp55 mutant with
retained RNA-binding domains, but without the RS domain,
should function equally well or better than wild-type SRp55.
Overexpression of SRp55-dRS, which lacks the RS domain,
failed to inhibit splicing andproduction of 13a7 vprmRNA (Fig.
9B). We concluded that the mechanism of inhibition of SD3 is
more complex than simply competing with SRp40 for binding
toGAR, because inhibitionwas dependent on the RS domain of
SRp55. Taken together, our results suggested that SRp55 inter-
acts with GAR and inhibits splicing from exon 3 by interacting
with an unidentified factor.


































































FIGURE 6. A, schematic representation of segments of the HIV-1 subgenomic plasmids pNL13a7 (7),
pNL13a7dG, and pNL13a7sd1dG. B and D, Northern blot with RNA extracted from HeLa cells transfected with
pNL13a7 (w) or pNL13a7dG (dg) in the absence or presence of CMV promoter-driven plasmids expressing
SRp40, SRp55, or SRp75. The blots were probed with exon 1 probe (Fig. 1A). All detected mRNAs are indicated.
C, RT-PCR with RNA extracted from HeLa cells transfected with pNL13a7 (w) or pNL13a7dG (dg) in the absence
or presence of CMV promoter-driven plasmids expressing SRp40, SRp55, or SRp75. RT-PCR oligonucleotides
Exon3s and BAMA (Fig. 1A) were used. The bands representing mRNAs are indicated. M represents the molec-
ular weight marker. E, RT-PCR with RNA extracted from HeLa cells transfected with pNL13a7sd1 (sd1) (Fig. 3A)
or pNL13a7sd1dG (sd1dg) in the absence or presence of CMV promoter-driven plasmid expressing SRp55.
Oligonucleotides used for RT-PCR were Exon1s and BAMA (Fig. 1A). Bands representing mRNAs are indicated.
M represents the molecular weight marker.
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To investigate if SRp55 and SRp75 were required for gener-
ation of the low levels of 13a7 vpr mRNA produced from
pNL13a7 in the absence of exogenous SRp55 or SRp75, we per-
formed an siRNA-mediated knockdown of endogenous SRp55
and SRp75 in cells transfected with pNL13a7. The results
revealed that the levels of unspliced 13a7 vpr mRNA produced
from the vpr cDNA pNL13a7 were reduced when SRp55 and
SRp75 levels were knocked down (Fig. 9C). A scrambled siRNA
and siRNAs against unrelated targets did not affect the levels of
13a7 vpr mRNA produced from pNL13a7 (data not shown).
These results suggest that knock-
down of SRp55 and SRp75 en-
hanced splicing of the 13a7 vpr
mRNA and support a role for SRp55
and SRp75 in the production of par-
tially spliced HIV-1 vpr mRNAs.
DISCUSSION
We show that overexpression of
SRp55 specifically inhibits splicing
from the 5-splice site of HIV-1
exon 3. High levels of SRp55 over-
ride all splicing enhancers in exons 4
and 5, including ESE2 (24) and GAR
(25, 26), causing splicing inhibition
from exon 3 and production of the
partially spliced 13a7 vpr mRNA.
We demonstrate that SRp55 inhib-
its GAR, suggesting a model in
which SRp55 interferes with the
GAR-enhancer to inhibit splicing to
exons 4a, 4b, 4c, and 5, at least from
the 5-splice site of exon 3. We also
found that SRp55 simultaneously
enhances splicing from exon 1 to
exon 4 to produce tat mRNA, sug-
gesting that production of tat
mRNA is less GAR-dependent than
rev and nef mRNAs and that SRp55
acts also on RNA elements in exon
4. We speculate that these interac-
tions inhibit splicing when the
5-splice sites is weak, as in exon 3
(Fig. 3A), whereas, in combination
with the stronger 5-splice site of
exon 1, these interactions redirect
splicing to exon 4. Although we
identified GAR as one target for the
splicing inhibitory effect of SRp55, it
remains to be determined how
SRp55 directs splicing from exon 1
to exon 4.
There are multiple splicing en-
hancer elements in exons 4 and 5
(16). Whereas SC35 binds to en-
hancer ESE2 (24), potential binding
sites for ASF/SF2, SRp40, and
SRp55 were identified in GAR (25).
Previously published in vitro splicing experiments revealed that
SRp40 and ASF/SF2 act through GAR (25, 26), whereas no
enhancing effect was seen with SRp55 (25). Our experiments
are in agreement with these published results and confirm that
deletion of GAR in subgenomic HIV-1 plasmids abrogates pro-
duction of rev and nef mRNAs, whereas tat mRNAs are unaf-
fected (25). In addition,we confirm thatGARcan act as a potent
splicing enhancer on heterologous mRNAs. We showed that
insertion of GAR downstream of the major HPV-16 3-splice























































































FIGURE 7. A, schematic representation of the HPV-16 subgenomic plasmids pT1sd and pT1sde (29) as well as
the HPV-16 subgenomic plasmid containing the HIV-1 exon 5 sequence, including the GAR sequence (25, 26),
pT1–5/GAR. The L1 and L1i mRNAs produced from these plasmids are indicated. Arrows indicate PCR oligonu-
cleotides 757s and L1AM used for RT-PCR. B, the HIV-1 sequence inserted in pT1sd is shown with the GAR
sequence indicated in bold. C, RT-PCR, with oligonucleotides 757s and L1AM, on RNA extracted from HeLa cells
transfected with pT1sd, pT1sde, or pT1–5/GAR in the absence or presence of CMV promoter-driven plasmid
expressing SRp55. Bands representing L1 or L1i mRNAs are indicated. M represents the molecular weight
marker. D, RT-PCR on RNA extracted from HeLa cells transfected with pT1–5/GAR in the absence or presence of
various concentrations of SRp55 plasmid. M represents the molecular weight marker.
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HPV-16. Previously published results demonstrated that GAR
was primarily dependent on ASF/SF2 and ASF/SF2-sites
located in GAR and at SA5 (25), whereas the SRp40 site in GAR
contributed less to GAR function. Other investigators have
demonstrated that SRp40 enhances splicing to exon 4 (39). Our
results confirm that overexpression of SRp40 enhances splicing to
SA4, at the expense of SA4a, SA4b, SA4c, and SA5. These results
suggest that SRp40 may act on multiple sites in exon 4, upstream
of SA5. Deletions that we introduced in exon 4 lowered the effect
of SRp40 (Fig. 5). So did the deletion of GAR (Fig. 6). One may
speculate that SRp40 interacts with multiple sites in exon 4,
including the site in GAR, to enhance
production of exon 4 containing tat
mRNAs.
SRp40 appears to induce pro-
duction of exon 4-containing tat
mRNA from various 5-splice sites.
Our experiments demonstrate that
SRp55 overrides the induction of tat
mRNA 1347 by SRp40. In the pres-
ence of high levels of SRp40 a strong
induction of splicing to exon 4 (SA4)
occurs. However, overexpression of
SRp55 inhibits splicing from SD3
even at high concentrations of
SRp40 and causes production of
13a7 vpr mRNA, demonstrating
that SRp40 and SRp55 are compet-
ing for the HIV-1 pre-mRNA. Simi-
larly, SRp55 overrides the potent
GAR enhancer that likely functions
so well in many cell types as a result
of high levels of endogenous ASF/
SF2. Although the predicted SRp55
binding site in GAR overlaps with
the SRp40 binding site, and binding
of SRp55 to this site may inhibit
binding of SRp40, it is questionable
if steric hindrance explains the
inhibitory effect of SRp55. Although
SRp55 binds to GAR and acts at
least partly through GAR, its mech-
anism of splicing inhibition is likely
to be more complex than mere
physical hindrance of binding of
other splicing factors to nearby
sites. This is also reflected by the
requirement for the SRp55 RS
domain for inhibition of splicing.
These results suggest that SRp55
interacts with an unknown factor to
inhibit splicing from the 5-splice
site of exon 3. This factor could be
another SR protein.
Overexpression of SR proteins
with the infectious molecular clone
pNL43 revealed that high levels of
ASF/SF2 induced production of vpr
mRNA, at the same time causing a dramatic decrease in gag,
pol, and env proteins as well as virus production (40). These
authors speculate that ASF/SF2 enhances splicing to the
3-splice site of exon 3, either through a yet unidentified splic-
ing enhancer, or by inhibiting a previously identified splicing
silencer in exon 3 named ESSV (10, 17). This splicing silencer
interacts with heterogeneous nuclear ribonucleoprotein A/B
(10, 17, 41), and ASF/SF2 is known to counteract heterogene-
ous nuclear ribonucleoprotein A1, another member of the het-
erogeneous nuclear ribonucleoprotein family (42, 43). How-
ever, ASF/SF2 binds to the GAR enhancer and is necessary for
gaagaagcggagacagcgacgaagagcucauca
SRp55 SRp40
gar + ++ ++ + ++
competitor











FIGURE 8. A, representation of GAR sequence used as probe for RNA gel shift assay. Potential binding sites for
SRp40 and SRp55 are indicated according to ESEfinder (37, 38). B, RNA gel shift assay with radiolabeled GAR
RNA and purified gst protein (gst) or purified gst SRp55 protein (gst SRp55). Increasing amounts of unlabeled
GAR RNA (competitor). Free and bound probe are indicated. C, RNA gel shift assay with radiolabeled HPV-1 RNA
named AUM/UM (34) and purified gst protein (gst) or purified gst SRp55 protein (gst SRp55). The AUM/UM RNA
is 57 nucleotides and has an AU content of 76%, and the sequence of the AUM/UM mRNA is the following:
AUACCUAUUAGUAGAUUACCUAUUAUAUAUUCCUAUAUUCCUAUACUUCCUAUACUU.
FIGURE 9. A, Northern blot with RNA extracted from HeLa cells transfected with plasmid pNL13a7 (7) (Fig. 1A) in
the absence or presence of CMV promoter-driven plasmid expressing SRp40 and serially diluted CMV pro-
moter-driven plasmids expressing SRp55 or SRp75. The blot was probed with exon 1 probe (Fig. 1A) detect-
ing all mRNAs. Identified mRNAs are indicated. B, acrylamide gel showing RT-PCR with oligonucleotides
Exon3s and BAMA (Fig. 1A) on cytoplasmic RNA from HeLa cells transfected with pDP (Fig. 2A) in the
absence or presence of CMV promoter-driven plasmid expressing SRp55 or SRp55-dRS, which is lacking
the RS domain. vpr, tat, and nef mRNAs are indicated. M represents the molecular weight marker.
C, agarose gels showing RT-PCR reactions with oligonucleotides Exon3s and BAMA (Fig. 1A) on cytoplas-
mic RNA from HeLa cells transfected with pNL13A7 in the absence or presence of 133 nM siRNA against
SRp55 and SRp75 (SMARTpool Dharmacon). The lower panel shows RT-PCR on cytoplasmic RNA from HeLa
cells transfected with pNL13A7 in the absence or presence of either 133 nM or 27 nM of siRNAs against
SRp55 and SRp75 (SMARTpool Dharmacon). The right panel shows RT-PCR on SRp55 mRNA in the absence
or presence of siRNAs against SRp55 and -75.
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splicing to exons 4a and 5 (25, 26). In contrast, overexpression
of ASF/SF2 promotes production of the partially spliced vpr
and overrides the function of GAR, much like SRp55 (39, 40).
Because both ASF/SF2 and SRp55 can bind to exon 5, one may
speculate that these interactions in combination with other
binding sites only occupied in the presence of high levels of
ASF/SF2 or SRp55, may inhibit splicing from exon 3 to exons 4,
4a, 4b, 4c, and 5 thereby creating the vpr mRNA. ASF/SF2 and
SRp55 may induce production of vpr mRNA in a similar man-
ner. In HIV-1-infected cells, levels of various SR proteins may
change during the infection (44), or HIV-1 has adapted to the
intracellular levels of SR proteins in T cells and monocyte/
macrophages to optimize production of sufficient quantities of
each alternatively spliced HIV-1 mRNA. Nevertheless, it is
clear that HIV-1 alternative splicing and virus production are
sensitive to minor changes in intracellular concentrations of
various SR proteins (40, 45).
Recently it was shown that splicing to exon 2A, another
incompletely spliced HIV-1 exon that encodes the vif gene,
appears to be positively regulated by SRp75 through the inter-
action of SRp75 with an enhancer in this region (46, 47). We
show that SRp75 can induce production of vprmRNAby inhib-
iting the 5-splice site of exon 3. Our experiments revealed that
deletions in exon 3 enhanced splicing from the 5-splice site of
exon 3 (Fig. 4). This is in line with previously published results
that identified a splicing silencer namedESSV in exon 3 (10, 12).
However, our results do not support an interaction between
SRp75 and sequences in exon 3. It appears that splicing of the
two partially spliced HIV-1 mRNAs 12a7 (vif) and 13a7 (vpr) is
differently regulated.
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Javier F. Cáceres for providing plasmids and Paul Jackman for par-
ticipating in some experiments.
REFERENCES
1. Schwartz, S., Felber, B. K., Benko, D. M., Fenyö, E. M., and Pavlakis, G. N.
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